1. Role: Director. Scope: Department. Date: 2019.
Grant H. Skrepnek, Ph.D., R.Ph.
Professor
Pharmacy Clinical & Admin Sci
Phone (405) 271-6878 x47105
Fax (4050 271-6430
Office CPB 214
Email grant-skrepnek@ouhsc.edu
Summary
I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Research
Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Publications & Presentations
- 76. Gilligan A M, Skrepnek G H. An analysis of security price risk and return among publicly traded pharmacy corporations. Research in social & administrative pharmacy : RSAP. 2013; 9 : 828-40
77. Barnes C J, Caon C, Foley J F, Friedman M, Menzin J, Nair K V, Nichols C, Olvey E L, Owens G M, Pill M W, Skrepnek G H, White L A, Zerkowski K. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care. Journal of managed care pharmacy : JMCP. 2013; 19 : S1-53
78. Armstrong E P, Skrepnek G H, Sasane M, Snodgrass S M, Ballas S K. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs. Journal of medical economics. 2013; 16 : 10-8
79. Owens G M, Olvey E L, Skrepnek G H, Pill M W. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. Journal of managed care pharmacy : JMCP. 2013; 19 : S41-53
80. Amini A, Patanwala A E, Maegawa F B, Skrepnek G H, Jie T, Gruessner R W, Ong E S. Effect of epidural analgesia on postoperative complications following pancreaticoduodenectomy. American journal of surgery. 2012; 204 : 1000-4; discussion 1004-6
Grants
- 1. [Cooperative Agreement] Oklahoma State Department of Health, A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes – 2023 (DP-23-0020, FAIN #NU58DP007376, CFDA #93.988 (Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems). . CDC. Start Date: 2023. End Date: 2024.
2. [Cooperative Agreement] Oklahoma State Department of Health, Chronic Disease Prevention Program: The National Cardiovascular Health Program (DP-23-0004, FAIN #NU58DP007471, CFDA #93.426 - The National Cardiovascular Health Program, CDV/Heart. CDC. Start Date: 2023. End Date: 2024.
3. HIV Adherence Services. Start Date: 2022. End Date: 2023.
4. Patterns of Care, Outcomes, and Barriers to Treatment Success or Vaccination Associated with Adult Community-Acquired Pneumonia in Medicaid. Misc Non-Federal. Start Date: 2021. End Date: 2022.
5. [Service Agreement] Opioid Use Under Oklahoma Senate Bill 848.. Non-federal. Start Date: 2020. End Date: 2020.
Awards and Honors
no results
Education
no results
Administrative Assignments
2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.